Results: A total of 26 patients were entered into the trial (15 males and 11 females mean age, 59.9 years age range, 41–81 years).
Patients were entered into one of four dosage tiers of 5, 10, 25, or 50 mg/m 2 sibrotuzumab, administered weekly for 12 weeks, with trace labeling with 8–10 mCi of 131I in weeks 1, 5, and 9.
Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-determining region grafted humanized antibody (sibrotuzumab) directed against human fibroblast activation protein (FAP).Įxperimental Design: A Phase I open-label dose escalation study was conducted in patients with cancers epidemiologically known to be FAP positive.
